Ascend Wellness Holdings (AAWH) Fair Value & Analysis
Healthcare · US · Market cap $108M
Fair value as of: Jun 25, 2026
Analysis
Ascend Wellness Holdings (AAWH) currently trades at $0.4400, while our model-based Fair Value estimate is $0.5204 — implying the stock looks roughly 18.3% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
About the company
Ascend Wellness Holdings, Inc. engages in the cultivation, manufacture, and distribution of cannabis consumer packaged goods in the United States. The company offers flower, pre-rolls, concentrates, vapes, edibles, tablets, and other cannabis-related products under the Common Goods, SimplyHerb, Ozone, Royale, High Wired, Effin', Miss Grass, Lowell Smokes, Flower by Edie Parker, 1906, AiroPro, and Miss Grass brands. It also owns, operates, and manages cannabis cultivation facilities and dispensaries. The company sells its products through company-owned retail stores, and third-party licensed retail cannabis stores. The company was formerly known as Ascend Wellness Holdings, LLC and changed its name to Ascend Wellness Holdings, Inc. in April 2021. Ascend Wellness Holdings, Inc. was incorporated in 2018 and is headquartered in Rochelle Park, New Jersey.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Ascend Wellness Holdings (AAWH) undervalued?
What is the fair value of AAWH?
What is the quality score of AAWH?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.